Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 15/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364914 | 1.00 | CCR4 (0.43) | CCR4CCR5EDNRAHTTKMT2A | |
| SCHEMBL11222657 | 0.83 | SIRT6 (0.37) | HTT | |
| SCHEMBL30416654 | 0.82 | CCR4 (0.45) | CCR4CCR5EDNRA | |
| SCHEMBL609085 | 0.82 | CCR4 (0.45) | CCR4CCR5EDNRA | |
| SCHEMBL13745097 | 0.80 | PIK3CA (0.35) | HTT | |
| SCHEMBL1870852 | 0.80 | ALDH1A1 (0.44) | HTTKMT2A | |
| SCHEMBL29597929 | 0.79 | CCR4 (0.42) | CCR4EDNRAHTTKMT2A | |
| SCHEMBL3149912 | 0.79 | CCR4 (0.42) | CCR4EDNRAHTTKMT2A | |
| SCHEMBL3146276 | 0.79 | PIK3CA (0.40) | CCR4 | |
| SCHEMBL15624611 | 0.78 | USP7 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4727652-A1 | (HETERO)ARYL-SULFONAMIDE COMPOUNDS AS MODULATORS OF GPR35 | ThirtyFiveBio Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12441730-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-5861401-A | TREATMENT OF CONGESTIVE HEART FAILURE | ZENECA LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| CN-1192739-A | N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists | ZENECA LTD (GB) | 1998-09-09 | — | — | CN | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| EP-0752986-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1997-01-15 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
| WO-1995026957-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1995-10-12 | — | — | WO | disclosed |
| US-4343802-A | ADRENERGIC BLOCKING, ANTIARRYHYTHMIA, AND CARDIOTONIC AGENTS | MERCK, SHARP & DOHME (I.A.) CORP. (US) | 1982-08-10 | — | — | US | disclosed |
| US-4193995-A | B-ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORP. (US) | 1980-03-18 | — | — | US | disclosed |
| US-4042586-A | ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORPORATION (US) | 1977-08-16 | — | — | US | disclosed |
| US-3946009-A | ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORPORATION (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | CCR4 4622/4885CCR5 3604/4885EDNRA 3964/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | CCR4 1150/4885CCR5 1345/4885EDNRA 3959/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | CCR4 1282/4885CCR5 1730/4885EDNRA 4189/4885 |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CCR4 960/4885CCR5 403/4885EDNRA 2239/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | CCR4 3979/4885CCR5 1523/4885EDNRA 58/4885 |
| US-12441730-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | CCR4 3574/4885CCR5 1217/4885EDNRA 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.